Cargando…

Oncolytic Adenovirus with SPAG9 shRNA Driven by DD3 Promoter Improved the Efficacy of Docetaxil for Prostate Cancer

Prostate cancer (PCa) is a common malignant tumor of the male urinary system and ranks the second in the causes of tumor-related deaths. Differential display code 3 (DD3) is a noncoding gene that is specifically expressed in PCa. High expression of sperm-associated antigen 9 (SPAG9) is closely relat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Meng, Wei, Fu-kun, Wu, Chuang, Xu, Zi-yang, Mao, Li-jun, Yang, Dong-rong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078851/ https://www.ncbi.nlm.nih.gov/pubmed/35535313 http://dx.doi.org/10.1155/2022/7918067

Ejemplares similares

Stable expression of shRNA for the control of recombinant adenovirus replication
por: Lana, M.V.G., et al.
Publicado: (2023)

shRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapy
por: Zhang, Jie, et al.
Publicado: (2016)

Downregulation of survivin by adenovirus-mediated shRNA promotes apoptosis in skin cancer cells
por: Hao, Yuqin, et al.
Publicado: (2019)

Construction of shRNA lentiviral vector
por: Song, Hong, et al.
Publicado: (2010)

Prostate Cancer-Specific of DD3-driven Oncolytic Virus-harboring mK5 Gene
por: Hao, Jiali, et al.
Publicado: (2018)

Prime-boost immunization by both DNA vaccine and oncolytic adenovirus expressing GM-CSF and shRNA of TGF-β2 induces anti-tumor immune activation
por: Kim, So Young, et al.
Publicado: (2017)

Oct4 and Hypoxia Dual-Regulated Oncolytic Adenovirus Armed with shRNA-Targeting Dendritic Cell Immunoreceptor Exerts Potent Antitumor Activity against Bladder Cancer
por: Hu, Che-Yuan, et al.
Publicado: (2023)

Optimized PCR Conditions and Increased shRNA Fold Representation Improve Reproducibility of Pooled shRNA Screens
por: Strezoska, Žaklina, et al.
Publicado: (2012)

Oncolytic adenovirus-mediated therapy for prostate cancer
por: Sweeney, Katrina, et al.
Publicado: (2016)

Oncolytic Adenovirus, a New Treatment Strategy for Prostate Cancer
por: Yang, Kaiyi, et al.
Publicado: (2022)

Oncolytic Adenovirus Harboring Interleukin-24 Improves Chemotherapy for Advanced Prostate Cancer
por: Mao, Li-jun, et al.
Publicado: (2018)

shRNA target prediction informed by comprehensive enquiry (SPICE): a supporting system for high-throughput screening of shRNA library
por: Kamatuka, Kenta, et al.
Publicado: (2016)

Combination Therapy of Prostate Cancer by Oncolytic Adenovirus Harboring Interleukin 24 and Ionizing Radiation
por: Mao, Li-jun, et al.
Publicado: (2020)

Adenovirus vectors lacking virus-associated RNA expression enhance shRNA activity to suppress hepatitis C virus replication
por: Pei, Zheng, et al.
Publicado: (2013)

Parallel shRNA and CRISPR-Cas9 screens enable antiviral drug target identification
por: Deans, Richard M., et al.
Publicado: (2016)

Combination of oncolytic adenovirus targeting SATB1 and docetaxel for the treatment of castration-resistant prostate cancer
por: Mao, Lijun, et al.
Publicado: (2021)

Optimization and characterization of tRNA-shRNA expression constructs
por: Scherer, Lisa J., et al.
Publicado: (2007)

Design and cloning strategies for constructing shRNA expression vectors
por: McIntyre, Glen J, et al.
Publicado: (2006)

The effects of stem length and core placement on shRNA activity
por: Mcintyre, Glen J, et al.
Publicado: (2011)

Optimization of Duplex Stability and Terminal Asymmetry for shRNA Design
por: Matveeva, Olga V., et al.
Publicado: (2010)

Energy profile and secondary structure impact shRNA efficacy
por: Zhou, Hong, et al.
Publicado: (2009)

Production of Transgenic Calves Expressing an shRNA Targeting Myostatin
por: Tessanne, K, et al.
Publicado: (2012)

Improved siRNA/shRNA Functionality by Mismatched Duplex
por: Wu, Haoquan, et al.
Publicado: (2011)

Suppression of Cancer Progression by MGAT1 shRNA Knockdown
por: Beheshti Zavareh, Reza, et al.
Publicado: (2012)

Using shRNA experiments to validate gene regulatory networks
por: Olsen, Catharina, et al.
Publicado: (2015)

Silencing Human Rb2/p130 with shRNA
por: Leucci, Eleonora, et al.
Publicado: (2007)

Multiplex CRISPR/Cas9-based genome engineering enhanced by Drosha-mediated sgRNA-shRNA structure
por: Yan, Qiang, et al.
Publicado: (2016)

Specific properties of shRNA-mediated CCR5 downregulation that enhance the inhibition of HIV-1 infection in combination with shRNA targeting HIV-1 rev
por: Cardona, Maria E., et al.
Publicado: (2022)

SPAG9 expression is increased in human prostate cancer and promotes cell motility, invasion and angiogenesis in vitro
por: Chen, Feifei, et al.
Publicado: (2022)

Oncolytic adenovirus coexpressing interleukin-12 and shVEGF restores antitumor immune function and enhances antitumor efficacy
por: Ahn, Hyo Min, et al.
Publicado: (2016)

Prostate Cancer-Specific and Potent Antitumor Effect of a DD3-Controlled Oncolytic Virus Harboring the PTEN Gene
por: Ding, Miao, et al.
Publicado: (2012)

Oncolytic Adenoviruses in Gastrointestinal Cancers
por: Yokoda, Raquel T., et al.
Publicado: (2018)

Oncolytic Adenoviruses in Cancer Treatment
por: Alemany, Ramon
Publicado: (2014)

Oncolytic Adenovirus in Cancer Immunotherapy
por: Peter, Malin, et al.
Publicado: (2020)

Oncolytic Adenoviruses for Cancer Therapy
por: Tripodi, Lorella, et al.
Publicado: (2021)

Concepts in Oncolytic Adenovirus Therapy
por: Mantwill, Klaus, et al.
Publicado: (2021)

A Renaissance for Oncolytic Adenoviruses?
por: Blanchette, Paola, et al.
Publicado: (2023)

Oncolytic adenovirus Ad657 for systemic virotherapy against prostate cancer
por: Nguyen, Tien V, et al.
Publicado: (2018)

Antithrombotic Effect of shRNA Target F12 Mediated by Adeno-Associated Virus
por: Li, Fanfan, et al.
Publicado: (2019)

Criteria for effective design, construction, and gene knockdown by shRNA vectors
por: Taxman, Debra J, et al.
Publicado: (2006)

Cannot write session to /tmp/vufind_sessions/sess_i3vpga4r1flmu7it7vc4htrfdv